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threshold accepted by the United Kingdom reimbursement agency. Further examination
of the resource use and treatment pathway in this patient group will help to reduce the
uncertainty in the ICER.
TCT-131
Transfemoral Transcatheter Aortic Valve Implantation Versus Surgical Aortic
Valve Replacement in Patients Severe Aortic Stenosis
Marco Barbanti, Gian Paolo Ussia, Davide Capodanno, Carmelo Mignosa, Valeria
Cammalleri, Marilena Scarabelli, Patrizia Aruta, Anna Maria Pistritto, Sebastiano
Immè, Simona Gulino, Salvatore Bonura, Alessandra Cadoni, Maria Concetta Di
Pasqua, Claudio Bonanno, Maurizio Gentile, Stefano Cannata, Corrado Tamburino
Ferrarotto Hospital, University of Catania, Catania, Italy
Background: A number of large single-arm registries demonstrated that short and
long-term outcomes after Transcatheter Aortic Valve Implantation (TAVI) have the
potential to compare favorably with surgical aortic valve replacement (SAVR) in high-
risk patients. No prospectively randomized trials comparing transcatheter techniques
to conventional SAVR are available, and direct comparisons of TAVI and SAVR remain
sparse.We sought to evaluate early and mid-term outcomes of transfemoral TAVI in
comparison with conventional SAVR.
Methods: Consecutive patients (n=770) who underwent TAVI (n=164) and SAVR
(n=606) at two centers were included in this analysis. Primary endpoint was major
adverse cerebrovascular and cardiac events (MACCE) at 30-day and 1-year.
Results: Procedural MACCE occurred in 122 patients (15.9%), being more frequent
in patients treated with SAVR compared to those treated with TAVI (9.1% vs 17.7%;
p=0.008). After addressing potential confounders by using three methods of statistical
adjustment, SAVR was generally associated with a trend towards a higher risk of
MACCE than TAVI, with estimates of risk ranging from 1.9 to 2.5 at 30 days, 1.9 to
2.6 at 6 months and 1.5 to 1.9 at 12 months. However, this difference was consistently
significant only at 6 months (p=0.049 after adjustment with covariates; p=0.026 after
adjustment with covariates and propensity score; p=0.042 after adjustment with
propensity score alone), driven by an adjusted reduced risk of life threatening bleeding
(adjusted HR 4.12; 95% CI 1.11-15.29). No differences in the adjusted risk of death,
MI and stroke were noted between TAVI and SAVR at each time point.
Conclusion: In a large observational registry with admitted potential for selection bias
and residual confounding, TAVI appeared to be safer than SAVR at mid-term follow-
up.
TCT-132
Intracardiac Echocardiography: a New Guiding Tool for Transcatheter Aortic
Valve Replacement
Thomas Bartel, Nicolaos Bonaros, Ludwig Müller, Guy Friedrich, Corinna Velik-
Salchner, Silvana Müller
Medical University Innsbruck, Innsbruck, Austria
Background: The aim of this study was to comparatively evaluate intraprocedural
guidance of transcatheter aortic valve replacement (TAVR) by intracardiac and
transesophageal echocardiography (ICE, TEE).
Methods: Fifty high-risk patients with severe aortic stenosis scheduled for TAVR were
randomized to either ICE guidance (figure: A - longitudinal axis, B - short axis; group
1; n = 25) or TEE monitoring (group 2; n = 25).
Results: ICE allowed continuous monitoring. The need for probe repositioning during
the procedure was much lower in group 1 (0.1 ± 0.3 vs. 5.7 ± 0.7 manoeuvres; P <
.001). The transcaval ICE view provided higher coaxiality with the ascending aorta
expressed by the length of ascending aorta depicted (4.9 ± 1.2 vs. 6.1 ± 1.2 cm, P =
.003). Both coronary ostia were more frequently visualized in group 1 (18 vs. 2 cases;
P < .001). ICE derived annulus measurements correlated tightly with preinterventional
TEE readings (n = 20, R = 0.90, P < .001). TEE underestimated intraprocedural
pressure gradients in comparison to preinterventional measurements (mean difference:
-10.2 ± 11.1 mm Hg, n = 11, P = .012), but ICE did not (mean difference: -0.3 ± 14.1
mm Hg, n = 25, P = .913). ICE and TEE detected newly grown thrombi (2 vs. 1 case).
Conclusion: ICE being compatible with sedation and local anesthesia can be
considered an alternative guiding tool to TEE. It also seems to match the required
workflow during TAVR better than TEE.
TCT-133
Management of Paravalvular Leaks During & After Transcatheter Valve
Replacement
Claudia A Martinez, Vikas Singh, Brian O’Neill, Alan W Heldman, William W
O’Neill
University of Miami, Miller School of Medicine, Miami, FL
Background: In an era of Transcatheter Aortic Valve Replacement (TAVR), aortic
paravalvular leak (PVL) represents a regurgitant space in between the frame of the
valve and the native tissues. Best practice to manage this important disorder is not yet
known.
Methods: Patients that underwent TAVR with Edwards SAPIEN (ES) aortic valve at
our center between April 2008 & May 2011 were identified retrospectively. The study
population consisted of those with either acute severe PVL requiring additional
maneuvers during the index TAVR procedure or symptomatic PVL requiring later
treatment by transcatheter closure. Transesophageal echocardiography (TEE) was used
to diagnose and plan the procedures. Procedural success was defined by a reduction in
the degree of PVL assessed by TEE.
Results: A total of 95 patients with TAVR were identified of which 21 required
intervention for PVL (13/21 had a 23 mm and 8/21 had a 26 mm ES valve). There was
no difference in the risk of developing PVR between the two valve sizes (22% for
each). 16/21 had severe PVL immediately after TAVR and underwent repeat balloon
post-dilatation of the implant during the index procedure, 5/21 patients underwent
“Valve in Valve” implantation of a second valve during the index procedure, 3/21
patients had PVL with refractory heart failure that required transcatheter closure
attempts 43 ±10 days after TAVR using vascular plugs, ventricular septal occluders or
coils. The most frequent location of PVL was posterior (non-coronary cusp> left cusp>
right cusp). A total of 26 procedures were performed: one patient required four and
two required two procedures each. The approach was retrograde in 17/26 (65%),
antegrade transeptal in 1/26 (3.8%) and antegrade transapical in 8/26 (30.7%). The
procedure was successful in 23/26 (88.5%) with a 30-day mortality of 1/21 (4.7%).
Peri-procedural complications occurred in 5/21 (23%), including acute kidney injury
requiring hemodialysis in 2, temporary complete heart block requiring pacing in 2, and
ischemic stroke in 1 patient.
Conclusion: PVL is a challenging complication after TAVR, when clinically significant
a variety of treatments can be applied, but dedicated tools may be required for optimal
management.
TCT-134
Immediate Results and Mid-term Follow-Up of Transcatheter Closure of
Paravalvular Leaks with Amplatzer Vascular Plug III Device
Manuel A Paulo, Jaime Dutary, Rosana Hernandez Antolin, Carlos Almeria, Ana
Cuadrado, Carlos Macaya, Eulogio Garcia
Interventional Cardiology, University Hospital San Carlos, Madrid, Spain
Background: Transcatheter closure of paravalvular leaks (PVL) is a recent therapeutic
option for high-risk surgical patients (P). The Amplatzer Vascular Plug III (AVP III)
device has shown safety for this purpose with good immediate results, but its mid and
long term efficacy need to be determined. The purpose of this study is to describe the
immediate results of a series of cases using the AVP III and clinical follow up.
Methods: Methods. Prospective, observational and single centre study of consecutive
P, between January 2008 and May 2011, with transcatheter PVL closure using the AVP
III device, immediate results and clinical follow-up.
Results: A total of 56 P were included (46 with mitral PVL, 7 P with aortic PVL and
3 P with mitral plus aortic PVL). Mean age was 68 ± 11 years. Mean logistic
EuroSCORE was 20±14. Eighty-four percent were in NYHA class III or IV. Clinical
indication was congestive heart failure plus severe haemolytic anemia in 71%. All
procedures except in 1 P (brachial access) were performed through femoral access.
Procedure was successful in 44 (93%) P, although in 29% more than one attempt was
required. There was only one major vascular complication and 1 P required new surgery
due to interference of the device with mitral prosthesis. At a mean follow-up (median
= 364 days, ICR = 125 – 617), majority of P (67%) were in functional class II or I.
Haemoglobin values were also increased at follow up (9.4 ± 1.6 pre vs. 10.4± 1.8 post
p=0.01), and free survival from cardiac death at 30 days, 6 months and 1 year was
96%, 84% and 80% respectively.
Conclusion: PVLs transcatheter closure with AVP III is safe with a high rate of
procedural success, following by acceptable clinical improvement at midterm follow-
up.
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